| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Ponvory | |
| 3 | Generic | ponesimod | |
| 4 | Indication | Relapsing Multiple Sclerosis. 2.3m WW, RMS is 85% | |
| 5 | Economics | Idorsia | |
| 6 | Clinical Trials | ||
| 7 | Phase III "OPTIMUM" n=1133 relapsing multiple sclerosis - ECTRIMS 2019 | ||
| 8 | 20mg ponesimod vs. 14mg teriflunomide | ||
| 9 | ARR primary endpoint at week 108 | ||
| 10 | ARR |